Blueprint Medicines Corp

Company Profile

Blueprint Medicines Corp had its IPO on 2015-04-30 under the ticker symbol BPMC.

The company operates in the Healthcare sector and Biotechnology industry. Blueprint Medicines Corp has a staff strength of 641 employees.

Stock update

Shares of Blueprint Medicines Corp opened at $44.76 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $44 - $45.63, and closed at $45.09.

This is a +0.22% increase from the previous day's closing price.

A total volume of 999,200 shares were traded at the close of the day’s session.

In the last one week, shares of Blueprint Medicines Corp have increased by +4.47%.

Blueprint Medicines Corp's Key Ratios

Blueprint Medicines Corp has a market cap of $2.70 billion, indicating a price to book ratio of 4.3665 and a price to sales ratio of 9.6137.

In the last 12-months Blueprint Medicines Corp’s revenue was $204.04 million with a gross profit of $177.28 million and an EBITDA of $-525783008. The EBITDA ratio measures Blueprint Medicines Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Blueprint Medicines Corp’s operating margin was -263.44% while its return on assets stood at -25.82% with a return of equity of -75.07%.

In Q4, Blueprint Medicines Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 63.8%.

Blueprint Medicines Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-9.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Blueprint Medicines Corp’s profitability.

Blueprint Medicines Corp stock is trading at a EV to sales ratio of 6.9888 and a EV to EBITDA ratio of -2.7283. Its price to sales ratio in the trailing 12-months stood at 9.6137.

Blueprint Medicines Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.35 billion

Total Liabilities

$183.23 million

Operating Cash Flow

$-53283000.00

Capital Expenditure

$1.48 million

Dividend Payout Ratio

0%

Blueprint Medicines Corp ended 2023 with $1.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.35 billion while shareholder equity stood at $514.68 million.

Blueprint Medicines Corp ended 2023 with $0 in deferred long-term liabilities, $183.23 million in other current liabilities, 60000.00 in common stock, $-1832958000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.71 million and cash and short-term investments were $944.99 million. The company’s total short-term debt was $27,430,000 while long-term debt stood at $535.28 million.

Blueprint Medicines Corp’s total current assets stands at $1.05 billion while long-term investments were $133.48 million and short-term investments were $825.28 million. Its net receivables were $23.53 million compared to accounts payable of $2.73 million and inventory worth $29.70 million.

In 2023, Blueprint Medicines Corp's operating cash flow was $-53283000.00 while its capital expenditure stood at $1.48 million.

Comparatively, Blueprint Medicines Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$45.09

52-Week High

$79.4

52-Week Low

$37.82

Analyst Target Price

$69.41

Blueprint Medicines Corp stock is currently trading at $45.09 per share. It touched a 52-week high of $79.4 and a 52-week low of $79.4. Analysts tracking the stock have a 12-month average target price of $69.41.

Its 50-day moving average was $45.22 and 200-day moving average was $53.08 The short ratio stood at 8.73 indicating a short percent outstanding of 0%.

Around 77.3% of the company’s stock are held by insiders while 10710.9% are held by institutions.